During the past decade, Sharp HealthCare conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 5 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sharp HealthCare" #1 sponsor was "Dendreon" with 3 trials, followed by "Cell Genesys" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Seagen Inc." with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sharp HealthCare" #1 collaborator was "Applied Health Research Centre" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Aventis Pharmaceuticals" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "GlaxoSmithKline" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Sharp HealthCare" are "Prostate Cancer" (6 trials), "Fallopian Tube Cancer" (2 trials), "Metastatic Cancer" (2 trials), "Metastatic Prostate Cancer" (2 trials) and "Ovarian Cancer" (2 trials). Many other conditions were trialed in "Sharp HealthCare" in a lesser frequency.

Most popular intervention types in "Sharp HealthCare" are "Drug" (21 trials), "Biological" (7 trials), "Device" (4 trials), "Other" (3 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Gemcitabine" (2 trials), "Simtuzumab" (2 trials), "ABR-215050, tasquinimod" (1 trials) and "APC-Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sharp HealthCare" are 17 trials for "All" genders, 11 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Sharp HealthCare". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Sharp HealthCare, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Sharp HealthCare, 1 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".